Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
NCT00816439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101
Last updated 2018-07-05
Summary
The cannabinoid type 1 (CB1) receptor is a protein found in the brain that is involved with the effects of marijuana; it may also play a role in the effects of alcohol dependence and withdrawal. Earlier animal studies have shown that although long-term alcohol use decreases the number of CB1 receptors in the brain, the number returns to normal after alcohol use stops. This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) scans to trace a radioactive chemical called \[11C\]MePPEP, which can locate and measure the number of CB1 receptors in the brain. Researchers will study the CB1 receptors in the brains of people with alcohol dependence, and compare the results to the CB1 receptors in the brains of people without alcohol dependence. The results of this study will be used to further research into appropriate treatment procedures for alcohol dependence.
This study will include 30 men with alcohol dependence and 50 men without alcohol dependence. All of the men must be between 18 and 65 years of age. Participants in both groups must not have any medical conditions that will prevent them from undergoing PET or MRI scans.
For the PET scan, participants will be injected with a small amount of \[11C\]MePPEP and will then be brought to the PET scanner. The scan will take between 3 and 4 hours, but participants will be allowed to take breaks over the course of the scan. The MRI scan will not require any injections and will take approximately 1 hour to complete.
Participants without alcohol dependence will make three visits to the National Institutes of Health Clinical Center. Blood and urine samples will be taken during one visit, and participants will arrange to have an MRI scan on one visit and a PET scan on the other visit, in whichever order they prefer.
Participants with alcohol dependence will undergo two PET scans: the first will be performed between 3 and 7 days after the participant last consumed alcohol, and the second will be performed approximately 2 to 4 weeks after the first scan (with no alcohol consumption permitted in the interval). Participants will alcohol dependence will also undergo an MRI scan and will provide blood and urine samples.
Conditions
- Alcoholism
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Principal Investigators
-
Robert B Innis, M.D. · National Institute of Mental Health (NIMH)
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-12-29
- Completion
- 2014-08-28
Countries
- United States
Study Locations
More Related Trials
-
Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
NCT01625611 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Intervention in Alcohol Use Disorder
NCT02168400 ·Status: COMPLETED ·Phase: NA
-
Effects of Cannabidiol in Alcohol Use Disorder
NCT03252756 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cerebellar Alterations in Individuals With a Cannabis Use Disorder
NCT02816034 ·Status: COMPLETED ·Phase: NA
-
The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients
NCT01560013 ·Status: UNKNOWN ·Phase: NA
-
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
NCT02616094 ·Status: COMPLETED ·Phase: NA
-
Neurobiology of Alcohol and Nicotine Co-Addiction
NCT03338933 ·Status: COMPLETED
-
Serotonin Transporters in Alcoholism
NCT00085865 ·Status: COMPLETED
-
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT00656487 ·Status: COMPLETED ·Phase: PHASE2
-
Using Imaging to Assess Effects of THC on Brain Activity
NCT03655717 ·Status: COMPLETED ·Phase: NA
-
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
NCT03662737 ·Status: COMPLETED
-
Cannabidiol in Youth Alcohol Use Disorder
NCT05317546 ·Status: COMPLETED ·Phase: PHASE2
-
Cannabidiol for Alcohol Use Disorder
NCT03904849 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Brain Functional Connectivity in Alcohol Use Disorder
NCT02877849 ·Status: COMPLETED
-
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
NCT05855668 ·Status: RECRUITING ·Phase: NA
-
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
NCT07148843 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
CBD for the Treatment of Alcohol Use Disorder
NCT04873453 ·Status: COMPLETED ·Phase: PHASE2
-
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation
NCT04412824 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Serotonin in Alcoholism
NCT00011752 ·Status: COMPLETED
-
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence
NCT05387148 ·Status: UNKNOWN ·Phase: PHASE2
-
Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)
NCT05937893 ·Status: COMPLETED ·Phase: NA
-
Neurofeedback & Alcohol Dependence
NCT02486900 ·Status: COMPLETED ·Phase: NA
-
Alcohol, Behavior, and Brain Imaging
NCT03930446 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics
NCT00001675 ·Status: COMPLETED
-
Cannabis Effects on Brain Morphology in Aging
NCT01874886 ·Status: COMPLETED